UY39676A - Moduladores de sting (estimulador de genes de interferón) - Google Patents

Moduladores de sting (estimulador de genes de interferón)

Info

Publication number
UY39676A
UY39676A UY0001039676A UY39676A UY39676A UY 39676 A UY39676 A UY 39676A UY 0001039676 A UY0001039676 A UY 0001039676A UY 39676 A UY39676 A UY 39676A UY 39676 A UY39676 A UY 39676A
Authority
UY
Uruguay
Prior art keywords
interferon gene
gene stimulators
sting modulators
compounds
sting
Prior art date
Application number
UY0001039676A
Other languages
English (en)
Inventor
Mehran Jalaie
Martin James Wythes
Ketan Satish Gajiwala
Chan Woo Huh
Ryan Lloyd Patman
Jianmin Sun
Eugene Yuanjin Rui
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY39676A publication Critical patent/UY39676A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

En la presente se proporcionan compuestos de la Fórmula general (I): , y sales aceptables desde el punto de vista farmacéutico de estos, procesos para la preparación de estos compuestos, composiciones que contienen estos compuestos y los usos de estos compuestos.
UY0001039676A 2021-03-18 2022-03-17 Moduladores de sting (estimulador de genes de interferón) UY39676A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163162640P 2021-03-18 2021-03-18
US202163165459P 2021-03-24 2021-03-24

Publications (1)

Publication Number Publication Date
UY39676A true UY39676A (es) 2022-10-31

Family

ID=80819922

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039676A UY39676A (es) 2021-03-18 2022-03-17 Moduladores de sting (estimulador de genes de interferón)

Country Status (17)

Country Link
US (1) US11964978B2 (es)
EP (1) EP4308563A1 (es)
JP (1) JP7554410B2 (es)
KR (1) KR20230146606A (es)
AU (1) AU2022238001A1 (es)
BR (1) BR112023017731A2 (es)
CA (1) CA3213427A1 (es)
CL (1) CL2023002737A1 (es)
CO (1) CO2023012198A2 (es)
CR (1) CR20230413A (es)
DO (1) DOP2023000194A (es)
EC (1) ECSP23070418A (es)
IL (1) IL306034A (es)
MX (1) MX2023010942A (es)
TW (1) TWI829112B (es)
UY (1) UY39676A (es)
WO (1) WO2022195462A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222644A1 (en) 2022-05-18 2023-11-23 F. Hoffmann-La Roche Ag Pyrazole derivatives as sting agonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TW201100411A (en) 2009-05-21 2011-01-01 Chlorion Pharma Inc Pyrimidines as novel therapeutic agents
CN105481983B (zh) 2010-09-09 2021-09-03 辉瑞公司 4-1bb结合分子
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US20190031765A1 (en) 2016-01-25 2019-01-31 Pfizer Inc. Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
WO2017175156A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
CA3024482A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
AU2018288018C1 (en) * 2017-06-22 2022-10-20 Curadev Pharma Limited Small molecule modulators of human STING
CN110016025B (zh) 2018-01-08 2021-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
EP3755331A4 (en) 2018-02-21 2021-11-17 The Scripps Research Institute AGONISTS OF THE STIMULATOR OF INTERFERON GENES (STING)
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
JP7326319B2 (ja) 2018-04-03 2023-08-15 メルク・シャープ・アンド・ドーム・エルエルシー Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物
CN112823036A (zh) 2018-07-03 2021-05-18 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
US11008344B2 (en) * 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
BR112021006905A2 (pt) 2018-10-11 2021-07-20 Ono Pharmaceutical Co., Ltd. composto, sal e solvato do mesmo e agente agonístico de sting, composição farmacêutica que compreende o dito composto e uso do mesmo para suprimir a progressão de, suprimir a recorrência de e/ou tratar câncer ou doença infecciosa
SG11202109452SA (en) * 2019-03-05 2021-09-29 F Star Therapeutics Inc Compounds, compositions, and methods for the treatment of disease
WO2020232375A1 (en) * 2019-05-16 2020-11-19 Silicon Swat, Inc. Oxoacridinyl acetic acid derivatives and methods of use
GEP20237572B (en) 2019-09-25 2023-11-27 Pfizer Polyheterocyclic modulators of sting (stimulator of interferon genes)

Also Published As

Publication number Publication date
AU2022238001A1 (en) 2023-09-14
US11964978B2 (en) 2024-04-23
JP7554410B2 (ja) 2024-09-20
CL2023002737A1 (es) 2024-04-01
US20220306641A1 (en) 2022-09-29
DOP2023000194A (es) 2023-11-30
CA3213427A1 (en) 2022-09-22
ECSP23070418A (es) 2023-10-31
MX2023010942A (es) 2023-09-28
WO2022195462A1 (en) 2022-09-22
TW202246262A (zh) 2022-12-01
JP2024509982A (ja) 2024-03-05
IL306034A (en) 2023-11-01
KR20230146606A (ko) 2023-10-19
BR112023017731A2 (pt) 2023-10-03
CR20230413A (es) 2023-10-13
CO2023012198A2 (es) 2023-11-30
EP4308563A1 (en) 2024-01-24
TWI829112B (zh) 2024-01-11

Similar Documents

Publication Publication Date Title
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
CL2018001484A1 (es) Dinucleotidas de purino ciclico como moduladores de estimulador de genes de interferon (sting).
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CL2020002352A1 (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
ECSP22022958A (es) Moduladores poliheterociclicos de sting (estimulador de genes de interferón)
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
DOP2021000088A (es) Compuestos de azalactam como inhibidores de hpk1
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
CO2023012198A2 (es) Moduladores de sting (estimulador de genes de interferón)
ECSP17069696A (es) Compuestos novedosos
CL2019000661A1 (es) Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
ECSP23088732A (es) Moduladores de trex1
CL2020001461A1 (es) Inhibidores de dopamina–b–hidroxilasa.
ECSP18056196A (es) Derivados de indano
CL2022003677A1 (es) Derivados de sulfona
ECSP22083926A (es) Compuestos útiles para inhibir la quinasa ret
AR124720A1 (es) Derivados de pirazolamida
CL2004000630A1 (es) Compuestos derivados de oxazol; sales de dichos compuestos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que contiene dichos compuestos; y su uso para inhibir el crecimiento tumoral.
AR122310A1 (es) Moduladores de sting (estimulador de genes de interferón)
AR129469A1 (es) Inhibidores de rock y sus usos
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
DOP2024000096A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno